The long read sequencing market was estimated at US$ 1.34 billion in 2026 and is projected to grow to US$ 15.14 billion by 2035, rising at a compound annual growth rate (CAGR) of 30.96% from 2026 to 2035.
Long-read sequencing (LRS) is one of the techniques of DNA sequencing in which the nucleotide sequence of long strands of DNA is determined. It is more favorable than short-read sequencing as it eliminates the need to cut up and then amplify the DNA. It can generate reads tens to thousands of kilobases in length with greater accuracy. These techniques implement different methodologies but are capable of sequencing long lengths of DNA. Long-read sequencing can more accurately detect large-scale mutations, where long sections of DNA are deleted or moved.
The increasing demand for genomics research due to rising incidences of genetic and chromosomal disorders boosts the market. In addition, the study of genetic variation and the discovery of mutations underlying human disease are dependent on technological advancements in molecular biology. The rising need for personalized medicines also potentiates LRS technology.
Opportunity for the Long Read Sequencing Market
Personalized or precision medicines are therapeutics that are tailored based on an individual’s clinical and genetic requirements. The rapidly changing demographics are one of the reasons for using personalized medicines. Genomic testing aids in identifying the risk of developing a disease later in life and taking early actions to help prevent or reduce its likelihood. LRS is used to detect and diagnose rare genetic disorders within the population. Apart from genetic disorders, long-read sequencing is also used to detect tumors and infectious diseases. It has also emerged as a valuable tool in the field of transplantation, particularly in understanding the complex interplay between donor and recipient immune systems. Hence, the technology opened the door for additional advancements and enhancements that may eventually result in clinical practice using personalized medicines.
Low Accuracy and High-Cost Hinder the Long Read Sequencing Market
The major challenge of the market is the low accuracy of LRS. The LRS technique is less accurate than short-read sequencing. Another major challenge is the high cost per base compared to short-read sequencing. The average cost of LRS is several thousand dollars. This limits the affordability of several researchers from low- and middle-income countries.
| Table | Scope |
| Market Size in 2026 | USD 1.34 Billion |
| Projected Market Size in 2035 | USD 15.14 Billion |
| CAGR (2026 - 2035) | 30.96% |
| Leading Region | North America by 43% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Product, By Technology, By Workflow, By Application, By End-Use, By Region |
| Top Key Players | 10x Genomics, Agilant Technologies, Azenta Life Sciences, BGI Genomics, Element Biosciences, Illumina, MGI, Oxford Nanopore Technologies, Pacific Biosciences (PacBio), Qiagen, Quantapore, Inc., Thermo Fisher Scientific, Universal Sequencing Technology Corporation |
| Segments | Shares % |
| Consumables | 48% |
| Instruments | 32% |
| Services | 20% |
By product, the consumables segment dominated the long read sequencing market by 48% share in 2025. Consumables for LRS include flow cells, assay kits, and reagents. They can eliminate the need to buy the entire sequencing kit.
The services segment is expected to grow at the fastest rate in the market during the forecast period. The availability of a lack of trained professionals and favorable infrastructure in small research institutions demands LRS services. In addition, the services can save a lot of time for researchers, allowing them to focus on outcomes rather than the procedure.
| Segments | Shares % |
| Nanopore Sequencing | 58% |
| Single Molecule Real Time Sequencing | 34% |
| Others | 8% |
By technology, the nanopore sequencing segment accounted for a considerable share of the long read sequencing market by 58% share in 2025. Nanopore sequencing is the only sequencing technology that enables real-time analysis in fully scalable formats, analyzes native DNA or RNA, and provides real-time analysis. In addition, it is proven with a variety of input materials such as genomic DNA, amplified DNA, cDNA, and native RNA.
The single molecule real-time sequencing segment is predicted to witness significant growth in the market over the forecast period. Single-molecule real-time (SMRT) sequencing minimizes chemical modifications during library preparation, eliminating the need for DNA amplification. It also allows for the detection of various types of epigenetic modifications.
| Segments | Shares % |
| Sequencing | 55% |
| Data Analysis | 28% |
| Pre-Sequencing | 17% |
By workflow, the sequencing segment led the global long read sequencing market by 55% share in 2025. Sequencing is one of the essential steps for LRS. Nucleotides are read on a sequencer at a read length and depth, and the clonal clusters are detected one base at a time.
The data analysis segment is anticipated to grow with the highest CAGR in the market during the studied years. Data analysis is the final step of the workflow. It involves analyzing the sequence reads produced by the sequencer. It involves two steps: read processing and sequence analysis.
| Segments | Shares % |
| Whole Genome Sequencing | 35% |
| Targeted Sequencing | 20% |
| RNA Sequencing | 15% |
| Metagenomics | 12% |
| Epigenetics | 10% |
| Others | 8% |
By application, the whole genome sequencing segment registered its dominance over the global long read sequencing market by 35% share in 2025. The rising demand for personalized medicines, identifying causative variants, and novel genome assembly boost the segment growth.
The metagenomics segment is projected to expand rapidly in the market in the coming years. The rising incidences of chronic disorders, disease prognosis research, and novel drug discovery augment the segment growth.
| Segments | Shares % |
| Academic & Research Institutes | 42% |
| Pharmaceutical & Biotechnology Companies | 31% |
| Hospitals & Clinics | 18% |
| Others | 9% |
By end-use, the academic & research institutes segment dominated the long read sequencing market by 42% share globally in 2025. The growing research and development in research institutions and the increasing number of publications & patents promote segment growth.
The pharmaceutical & biotechnology companies segment is anticipated to grow fastest in the market during the forecast period. Companies that have favorable infrastructure, sufficient funding, and research facilities augment segment growth.
North America held the largest share of the long read sequencing market by 43% share in 2025. The state-of-the-art research & development facilities, increasing investments & collaborations, and the presence of key players drive the market. The key players, such as PacBio, Azenta, Thermo Fisher Scientific, and Illumina, hold a major share of the global market. Novel drug discovery research and increasing awareness of personalized medicines boost the market. The market is also driven by favorable government policies and regulatory approvals for personalized medicines. In 2022, the US FDA approved 12 novel personalized medicines, accounting for 34% of all newly approved therapeutics. Out of which, 5 were new cell and gene therapies.
Asia-Pacific is projected to host the fastest-growing long read sequencing market by 21% share in the coming years. The rising geriatric population, increasing genetic and chromosomal disorders, and growing research and development drive the market. The market is also driven by favorable government policies to support genomics in respective nations. As of January 2024, whole genome sequencing of 10,074 individuals across 99 communities was completed under the ‘GenomeIndia Project.’ China's government also actively supports genomic research. In 2016, it announced a $9 billion, 15-year project to collect, analyze, and sequence genomic data to become a global leader in precision medicine. Similarly, the Japanese government supports the advancement of genomic research and the strengthening of collaboration with international research communities.
Europe is expected to grow significantly in the long read sequencing market by 27% share during the forecast period. The industries in Europe are focusing on various research and development by using long-read sequencing for new treatment and diagnostic option development for the rising genetic diseases. At the same time, institutes are also collaborating with them to enhance this production. Thus, all these factors, along with the rising use of personalized medication, are promoting the market growth.
| Tier 1 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| Oxford Nanopore Technologies | Oxford, England | United Kingdom | Global pioneer in nanopore-based single-molecule long-read sequencing with portable to high-throughput platforms | MinION, GridION, PromethION sequencing systems |
| Pacific Biosciences (PacBio) | Menlo Park, California | United States | Leader in HiFi long-read sequencing with industry-leading accuracy for structural variant and de novo assembly applications | Sequel II/IIe systems, HiFi sequencing technology |
| Illumina | San Diego, California | United States | Dominant sequencing company expanding into long-read adjacent technologies via synthetic and complete long-read solutions | NovaSeq systems, Complete Long Read technology |
| Tier 2 | ||||
| Thermo Fisher Scientific | Waltham, Massachusetts | United States | Major life sciences tools provider with sequencing-related instruments and sample prep ecosystems supporting long-read workflows | Ion Torrent platforms, library prep kits |
| QIAGEN | Hilden, North Rhine-Westphalia | Germany | Key enabler of sequencing workflows through sample preparation, extraction, and bioinformatics solutions | Sample prep kits, bioinformatics pipelines |
| 10x Genomics | Pleasanton, California | United States | Provides linked-read and single-cell technologies that complement long-read sequencing applications in genomics research | Chromium platform, single-cell genomics solutions |
| Tier 3 | ||||
| Singular Genomics | San Diego, California | United States | Emerging sequencing platform company focused on high-speed short-read systems with potential long-read adjacency in workflows | G4 sequencing platform |
| Element Biosciences | San Diego, California | United States | Innovative sequencing company challenging incumbents with cost-efficient high-throughput sequencing technology | AVITI sequencing system |
| Tier 1 | Tier 2 | Tier 3 | |
| Competitive Influence Share | 70–80% | 15–25% | 5–10% |
In January 2024, PacBio CEO Christian Henry announced that it more than doubled its fourth-quarter sales of $58.4 million, i.e., a 113% increase compared to $27.4 million collected in the last three months of 2022. This surge in revenue was attributed to the recently launched two major DNA sequencing machines. He also said that he expects to see long-read DNA sequencing take as much as half of the market within the next five years.
By Product
By Technology
By Workflow
By Application
By End-Use
By Region
Principal Consultant
Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and strategy.
Learn more about Shivani Zoting
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
+1 804-441-9344
